Tivantinib is primarily investigated for its potential as a targeted therapy in cancer treatment, specifically for cancers driven by the c-MET receptor tyrosine kinase. It has shown promise in clinical trials for hepatocellular carcinoma (HCC), where it targets and inhibits c-MET signaling, which is often overexpressed in this type of cancer. Additionally, tivantinib has been explored in non-small cell lung cancer (NSCLC) and other solid tumors with c-MET dysregulation. Its application focuses on improving outcomes in patients with advanced or metastatic disease, particularly those who have failed prior therapies. Research continues to evaluate its efficacy, safety, and potential combination with other anticancer agents.